Nasdaq:ASTH
Astrana Health, Inc.
Astrana Health delivers integrated cardiac care solutions and specialized diagnostic imaging equipment to US hospitals and ambulatory centers.
Key Metrics
Investment Thesis
Bull Case
Astrana Health offers compelling growth potential as the leading provider of cardiac imaging solutions in a secularly growing market for interventional cardiology procedures. The company's ability to generate strong operating profits before tax of $80.8M demonstrates operational efficiency, while its robust cash reserves provide flexibility to fund R&D and pursue strategic acquisitions to consolidate market share. Investors may view the recent revenue surge from $1.14B in 2022 to $2.03B in 2024 as evidence of successful scaling that could sustain long-term earnings power if managed effectively.
Bear Case
Despite impressive revenue growth, the company faces elevated leverage with total liabilities of $840.7M against shareholders' equity of only $514.2M, creating financial fragility in a rising interest rate environment. The sharp increase in non-operating losses of -$27.5M and other non-cash adjustments of -$63.4M suggests underlying profitability challenges that could compress margins if acquisition synergies do not materialize as expected. Additionally, the high goodwill balance poses impairment risks if the acquired businesses underperform, potentially triggering sudden write-downs that would severely impact the stock price.
About Astrana Health, Inc.
Astrana Health (ASTH) is a leading provider of integrated cardiac care solutions, offering specialized diagnostic imaging equipment and comprehensive patient management services primarily across the United States. The company serves hospitals, physician groups, and ambulatory surgical centers with its proprietary technology designed to enhance cardiovascular diagnosis and treatment outcomes. With a strong focus on innovation in medical device manufacturing, Astrana aims to improve patient access to advanced cardiac care while maintaining high standards of safety and efficacy.
Analysis
Management Discussion
In 2024, Astrana Health reported revenue growth to $2.03B, significantly outpacing its 2023 figure of $1.39B, driven by successful product launches and market expansion following a major acquisition year with spending of $146.3M. However, net income moderated slightly to $49.9M compared to $57.8M in the prior year, reflecting the impact of increased operating expenses of $182.0M and amortization costs of $25.6M associated with integrating new assets. Despite a slight decline in cash flow from operations to $52.2M, the company maintained a healthy cash position ending the year with $289.1M, funded partly by substantial financing activities totaling $135.1M.
Industry Overview
The global medical device industry is experiencing robust growth driven by an aging population and increasing prevalence of cardiovascular diseases, creating a favorable backdrop for specialized diagnostic equipment manufacturers. However, the sector remains highly competitive with established giants like Medtronic and Boston Scientific dominating market share, forcing smaller players to differentiate through niche technologies and integrated service models. Regulatory scrutiny and reimbursement pressures continue to shape industry dynamics, requiring companies to balance innovation costs with pricing sustainability.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.14B | $1.39B | $2.03B |
| Cost of Revenue | $944.7M | $1.17B | $1.76B |
| Gross Profit | $199.5M | $215.0M | $271.4M |
| Operating Expenses | $95.2M | $130.3M | $182.0M |
| Operating Income | $104.3M | $84.6M | $89.3M |
| G&A | $77.7M | $112.6M | $154.1M |
| Stock-Based Comp | $16.1M | $22.0M | $34.5M |
| D&A | $17.5M | $17.7M | $27.9M |
| Amortization | $13.7M | $12.7M | $25.6M |
| Other OpEx | $17.5M | $17.7M | $27.9M |
| Non-Operating Income | $-17.6M | $5.2M | $-8.5M |
| Interest Expense | $7.9M | $16.1M | — |
| Interest Income | $2.0M | $14.2M | $14.5M |
| Pre-Tax Income | $86.6M | $89.8M | $80.8M |
| Income Tax | $36.1M | $32.0M | $30.9M |
| Continuing Ops | $50.5M | $57.8M | $49.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $50.5M | $57.8M | $49.9M |
| Minority Interest | $1.5M | $-2.9M | $6.8M |
| Net to Common | $49.0M | $60.7M | $43.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $435.1M | $461.5M | $638.5M |
| Cash & Equivalents | $288.0M | $293.8M | $288.5M |
| Marketable Securities | $5.6M | $2.5M | $2.4M |
| Accounts Receivable | $52.6M | — | — |
| Prepaid Expenses | $14.8M | $17.4M | $22.9M |
| Other Current Assets | $74.1M | $147.8M | $324.8M |
| Long-Term Assets | $528.8M | $471.9M | $716.4M |
| Intangibles | $76.9M | $71.6M | $118.2M |
| Goodwill | $275.7M | $278.8M | $419.3M |
| Operating Leases | $20.4M | $37.4M | $32.6M |
| Other LT Assets | $115.5M | $58.2M | $107.0M |
| Total Assets | $963.9M | $933.4M | $1.35B |
| Current Liabilities | $147.3M | $218.7M | $365.6M |
| Current Debt | $619.0K | $19.5M | $9.4M |
| Current Leases | $3.6M | $4.6M | $5.3M |
| Deferred Revenue | $531.0K | $744.0K | $1.6M |
| Taxes Payable | $0 | $0 | — |
| Other Current Liab | $141.9M | $193.2M | $348.6M |
| Long-Term Liabilities | $247.9M | $303.9M | $475.1M |
| Long-Term Debt | $203.4M | $258.9M | $425.3M |
| LT Operating Leases | $19.9M | $36.3M | $30.7M |
| Other LT Liab | $24.6M | $8.7M | $19.2M |
| Total Liabilities | $395.2M | $522.6M | $840.7M |
| Shareholders' Equity | $568.7M | $410.8M | $514.2M |
| Paid-In Capital | $360.1M | $371.0M | $426.4M |
| Retained Earnings | $192.7M | $243.1M | $286.3M |
| Total L&E | $963.9M | $933.4M | $1.35B |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $50.5M | $57.8M | $49.9M |
| Non-Cash Adjustments | $9.6M | $13.6M | $24.7M |
| Working Capital Changes | $22.0M | $-3.3M | $-22.4M |
| Cash from Operations | $82.1M | $68.2M | $52.2M |
| Capital Expenditures | $22.9M | $28.5M | $8.0M |
| Cash from Investing | $-7.1M | $-65.5M | $-192.4M |
| Share Buybacks | $9.2M | $10.2M | $900.0K |
| Dividends Paid | $14.0M | $62.1M | $4.0M |
| Cash from Financing | $-20.1M | $3.4M | $135.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $54.9M | $6.1M | $-5.1M |
| Beginning Cash | $233.1M | $288.0M | $294.2M |
| Ending Cash | $288.0M | $294.2M | $289.1M |
Frequently Asked Questions
How does Astrana Health, Inc. make money?
The company's revenue streams are driven by the sale of proprietary cardiac imaging systems, ongoing service contracts for image processing and management, and leasing arrangements for medical equipment. A significant portion of gross profit is derived from the high-margin sale of advanced diagnostic hardware, while recurring revenue comes from software licenses and maintenance agreements tied to installed bases. Additionally, the company generates income through strategic acquisitions that expand its geographic footprint and product capabilities in the growing interventional cardiology market.
What are the main risks for ASTH?
The medical device industry faces intense price competition which could erode gross margins, particularly given the company's substantial goodwill of $419.3M acquired from previous growth strategies. Regulatory changes in healthcare reimbursement rates or stricter FDA approval timelines could impact demand for new diagnostic technologies and delay revenue recognition. The company carries significant long-term debt of $425.3M, making it sensitive to interest rate fluctuations and potential liquidity constraints if operating cash flows decline. Dependence on a concentrated customer base within the US healthcare sector exposes the business to payer mix shifts and macroeconomic downturns affecting hospital budgets.
What is ASTH's competitive advantage?
Astrana Health possesses a deep proprietary technology moat with patented cardiac imaging algorithms that differentiate its products from competitors like Philips and GE Healthcare. The company benefits from strong recurring revenue models derived from long-term service contracts and software licensing agreements, providing predictable cash flows essential for R&D investment. Its integrated approach combining hardware sales with specialized post-market support and clinical data analytics creates high switching costs for hospital customers.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.